AU2020378207A1 - Exon skipping of Fc-epsilon-RI-beta and MS4A6A in combination for the treatment of allergic diseases - Google Patents

Exon skipping of Fc-epsilon-RI-beta and MS4A6A in combination for the treatment of allergic diseases Download PDF

Info

Publication number
AU2020378207A1
AU2020378207A1 AU2020378207A AU2020378207A AU2020378207A1 AU 2020378207 A1 AU2020378207 A1 AU 2020378207A1 AU 2020378207 A AU2020378207 A AU 2020378207A AU 2020378207 A AU2020378207 A AU 2020378207A AU 2020378207 A1 AU2020378207 A1 AU 2020378207A1
Authority
AU
Australia
Prior art keywords
sequence
fcεriβ
ms4a6a
exon
antisense oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020378207A
Other languages
English (en)
Inventor
Glenn P. Cruse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University filed Critical North Carolina State University
Publication of AU2020378207A1 publication Critical patent/AU2020378207A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020378207A 2019-11-08 2020-11-09 Exon skipping of Fc-epsilon-RI-beta and MS4A6A in combination for the treatment of allergic diseases Pending AU2020378207A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932664P 2019-11-08 2019-11-08
US62/932,664 2019-11-08
PCT/US2020/059682 WO2021092562A1 (en) 2019-11-08 2020-11-09 Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases

Publications (1)

Publication Number Publication Date
AU2020378207A1 true AU2020378207A1 (en) 2022-06-23

Family

ID=75849333

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020378207A Pending AU2020378207A1 (en) 2019-11-08 2020-11-09 Exon skipping of Fc-epsilon-RI-beta and MS4A6A in combination for the treatment of allergic diseases

Country Status (6)

Country Link
US (1) US20220380777A1 (https=)
EP (1) EP4054639A4 (https=)
JP (1) JP2023501347A (https=)
CN (1) CN115335078A (https=)
AU (1) AU2020378207A1 (https=)
WO (1) WO2021092562A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136435A1 (en) 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法
CN120019145A (zh) * 2022-09-28 2025-05-16 阿塔兰塔治疗公司 用于治疗神经炎性疾病的组合物和方法
CN116219009B (zh) * 2022-10-19 2024-10-01 杭州师范大学 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137566A1 (en) * 2001-12-10 2004-07-15 Tedder Thomas F. Identification of novel ms4a gene family members expressed by hematopoietic cells
EP2933332A1 (en) * 2004-06-28 2015-10-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP2290087A3 (en) * 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
CN103074422A (zh) * 2012-12-29 2013-05-01 深圳市第三人民医院 Ms4a6a基因的用途
WO2017136435A1 (en) * 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
CN105969901B (zh) * 2016-07-27 2019-10-11 北京泱深生物信息技术有限公司 Ms4a6a作为多发性骨髓瘤诊治标志物的用途
EP3841198A4 (en) * 2018-04-13 2022-03-02 Rene Anand REAGENTS AND METHODS FOR AUTISM AND ITS COMORBIDITIES

Also Published As

Publication number Publication date
JP2023501347A (ja) 2023-01-18
EP4054639A1 (en) 2022-09-14
EP4054639A4 (en) 2025-04-30
WO2021092562A1 (en) 2021-05-14
CN115335078A (zh) 2022-11-11
US20220380777A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
US11596609B2 (en) Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
US20230346928A1 (en) Mrna combination therapy for the treatment of cancer
US20220380777A1 (en) Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases
KR102825946B1 (ko) IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
CN101557831A (zh) 体内抑制在灵长类亨廷顿基因表达的方法和序列
EP3394093B1 (en) Methods of using ox40 ligand encoding polynucleotides
US20190241658A1 (en) Therapeutic mRNAs encoding anti CTLA-4 antibodies
US6025193A (en) Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression
KR20210110310A (ko) 올리고머 핵산 분자 및 그의 이용
US20220372492A1 (en) Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
US20210363531A1 (en) Targeting kit with splice switching oligonucleotides to induce apoptosis of mast cells
US10537591B2 (en) Method for promoting muscle regeneration
US20150118744A1 (en) Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector
JPH09501057A (ja) 新規のオリゴヌクレオチド相互作用による血管細胞接着分子の発現の調節
JP2002519439A (ja) Ｉｌ−１５に標的されたアンチセンスオリゴヌクレオチド
WO2022022617A1 (en) Combinatory treatment of sma with sarna and mrna modulators
RU2839162C2 (ru) Молекула олигомерной нуклеиновой кислоты и ее применение
HK40092520A (zh) Sarna和mrna调节剂联合治疗sma
WO2024036343A2 (en) Synergistic nucleic acid based therapeutics and methods of use for treating genetic disorders
WO2024051765A1 (zh) 一种cd59基因沉默的t细胞及其应用
WO2026096962A1 (en) Methods and compounds for treating, ameliorating and/or preventing fibrotic diseases
US20240002848A1 (en) Compositions and methods for suppressing msutz
HK1260714B (en) Methods of using ox40 ligand encoding polynucleotides
HK1260714A1 (en) Methods of using ox40 ligand encoding polynucleotides